---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-005975"
form_type: "8-K"
ticker: "BCRX"
cik: "0000882796"
company_name: "BIOCRYST PHARMACEUTICALS INC"
filed_at: "2024-11-04T23:59:59+00:00"
generated_at: "2026-05-30T06:41:49.302865+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# BioCryst Q3: ORLADEYO revenue $116.3M (+35.7%); raises FY total revenue guide to $443-448M

## Summary
- Q3 total revenue $117.1M (+35.1% yoy) led by ORLADEYO net revenue of $116.3M.
- GAAP operating profit of $7.7M vs. loss of $11.9M in Q3 2023; non-GAAP op. profit $24.9M.
- Net loss narrowed to $14.0M ($0.07 per share) from $36.1M ($0.19) a year ago.
- FY 2024 ORLADEYO revenue guidance raised to $430-435M (top end of prior range); total revenue $443-448M.
- Pipeline: BCX17725 for Netherton syndrome entered clinic; avoralstat for DME on track for 2025.

## SEC filing metadata
- accession: 0001171843-24-005975
- form_type: 8-K
- ticker: BCRX
- cik: 0000882796
- company_name: BIOCRYST PHARMACEUTICALS INC
- filed_at: 2024-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882796/000117184324005975/0001171843-24-005975-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882796/000117184324005975/f8k_110424.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-005975
- JSON: https://secwatch.observer/filing/0001171843-24-005975.json
- Plain text: https://secwatch.observer/filing/0001171843-24-005975.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.